source
- Medicare rule could bring subcutaneous Keytruda and Opdivo under price negotiationsA federal rule proposed for 2029 aims to close a loophole that currently shields medicines moving from intravenous to subcutaneous administration from Medicare price negotiations. The Centers for M…
- J&J's Talvey plus Darzalex Faspro cuts death risk by up to 53% in relapsed multiple myelomaJohnson & Johnson reported that a combination of its immunotherapy Talvey with Darzalex Faspro, with or without Pomalyst, significantly lowered the risk of death in patients with relapsed or refrac…